Why BioTelemetry (BEAT) Is Spiking Today

NEW YORK (TheStreet) -- BioTelemetry (BEAT) was rising 14.52% to $11.28 on Thursday after the company reported fourth-quarter results that surpassed analysts' expectations.

BioTelemetry, which provides products and services to healthcare professionals to help diagnose and monitor patients, reported adjusted earnings per share of 5 cents, an improvement from the loss of 9 cents in the same period one year earlier. Revenue increased 10.3% year-over-year to $33.1 million. These figures beat the consensus estimate of a loss of 4 cents a share on revenue of $32.26 million.

"Looking forward, we enter 2014 with considerable momentum to execute on our strategic plan. We expect to take additional market share and further solidify our position as the industry's technology leader," said President and CEO Joseph Capper in the company's statement. "We have never been better positioned to compete and we expect to have another successful year in 2014." 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates BIOTELEMETRY INC as a "sell" with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate BIOTELEMETRY INC (BEAT) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow."

If you liked this article you might like

The BEAT Goes on at BioTelemetry

Buyers Get Picky About Bargains

Shark Bites: Two Big Movers

Shark Bites: Two Big Movers

Ignore Market Jitters, Let Price Action Be the Guide